BACKGROUND: Patients with head and neck squamous cell carcinoma (HNSCC) commonly have an imbalance in T helper (Th)1/Th2-type cytokines and elevated levels of CD4(+) CD25(high) regulatory T cells (Treg). Here, we investigated the association of circulating interleukin (IL)10, IL12, and Treg-cells with clinical outcome in patients with HNSCC. METHODS: Serum cytokine levels were determined by enzyme-linked immunosorbent assay (ELISA) in patients' pretreatment (n = 107) and 4 to 6 weeks posttreatment (n = 43), and in nontumor controls (n = 40). Treg-cell levels were determined by flow cytometry. RESULTS: IL10 detectability was significantly higher in patients than controls (p = .001). Pretreatment IL10 levels in all anatomical subsites, except the oral cavity, were significantly elevated in stages III/IV, N+ patients, and in T3/4-tumors (p = .005, .037, and .001, respectively). The detectability of IL10 significantly correlated with poorer survival after a maximum follow-up of 36 months. Treg-cell levels did not correlate with any clinical parameters. CONCLUSION: IL10 is a potential independent factor in predicting a poor clinical outcome in newly presenting tumors of laryngeal and pharyngeal origin. The role of circulating Treg-cells as predictors of clinical outcome requires further investigation.
BACKGROUND:Patients with head and neck squamous cell carcinoma (HNSCC) commonly have an imbalance in T helper (Th)1/Th2-type cytokines and elevated levels of CD4(+) CD25(high) regulatory T cells (Treg). Here, we investigated the association of circulating interleukin (IL)10, IL12, and Treg-cells with clinical outcome in patients with HNSCC. METHODS: Serum cytokine levels were determined by enzyme-linked immunosorbent assay (ELISA) in patients' pretreatment (n = 107) and 4 to 6 weeks posttreatment (n = 43), and in nontumor controls (n = 40). Treg-cell levels were determined by flow cytometry. RESULTS:IL10 detectability was significantly higher in patients than controls (p = .001). Pretreatment IL10 levels in all anatomical subsites, except the oral cavity, were significantly elevated in stages III/IV, N+ patients, and in T3/4-tumors (p = .005, .037, and .001, respectively). The detectability of IL10 significantly correlated with poorer survival after a maximum follow-up of 36 months. Treg-cell levels did not correlate with any clinical parameters. CONCLUSION:IL10 is a potential independent factor in predicting a poor clinical outcome in newly presenting tumors of laryngeal and pharyngeal origin. The role of circulating Treg-cells as predictors of clinical outcome requires further investigation.
Authors: Ayman J Oweida; Laurel Darragh; Andy Phan; David Binder; Shilpa Bhatia; Adam Mueller; Benjamin Van Court; Dallin Milner; David Raben; Richard Woessner; Lynn Heasley; Raphael Nemenoff; Eric Clambey; Sana D Karam Journal: J Natl Cancer Inst Date: 2019-12-01 Impact factor: 13.506
Authors: Donald T Weed; Paolo Serafini; Jennifer L Vella; Isildinha M Reis; Adriana C De la Fuente; Carmen Gomez; Zoukaa Sargi; Ronen Nazarian; Joseph Califano; Ivan Borrello Journal: Clin Cancer Res Date: 2014-10-15 Impact factor: 12.531
Authors: Bastian Schilling; Malgorzata Harasymczuk; Patrick Schuler; James E Egan; Theresa L Whiteside Journal: J Mol Med (Berl) Date: 2011-09-14 Impact factor: 4.599